Arabic Arabic English English French French German German
dark

Jounce Therapeutics Reports First Quarter 2021 Financial Results

Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Documentary Exposes the Alarming Truth — TV Puts Us In Hypnotic State and Suppresses Critical Thinking

Next Post

Standard Bariatrics® Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance

Related Posts
Total
0
Share